GREENFIELD, Ind., Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
On Thursday, February 29, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2024 Animal Health Summit at 2:10 p.m. ET.
On Monday, March 4, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 10:30 a.m. ET.
On Tuesday, March 12, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference at 4:05 p.m. ET.
Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will be available for approximately 30 days.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Katy Grissom (317) 273-9248 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$21.49 |
| Daily Change: | -0.03 -0.14 |
| Daily Volume: | 7,146,276 |
| Market Cap: | US$10.680B |
November 05, 2025 October 24, 2025 September 23, 2025 August 27, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
